BFRI - Biofrontera extends rally to reach a post-IPO peak

Micro-cap biopharma stock, Biofrontera (BFRI +66.9%) has stretched its pre-market gains to a post-IPO high on above average volume maintaining its popularity on social media. The company did not immediately respond to Seeking Alpha’s requests for comments on the sudden move in its share price. About 89.4M company shares have changed hands, more than four time the 65-day average volume of ~21.7M. According to sites that track mentions of ticker symbols, Biofrontera (NASDAQ:BFRI) has continued its lead as one of the top five stocks in terms of  the number of citations on Twitter over the past hour. The company did not not immediately respond to Seeking Alpha’s requests for comments on the sudden move in its share price. Since its trading debut in October, Biofrontera (BFRI), a commercial stage biopharma company focused on treatments for dermatological conditions has more than doubled in value. Its stock jumped nearly 100% in value

For further details see:

Biofrontera extends rally to reach a post-IPO peak